BioCentury | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

...VC PPF Group, as well as Partners Investment and additional undisclosed investors. Alongside the financing, Cellestia Biotech AG...
...million in non-dilutive funding. CFO Gaudenz von Capeller told BioCentury the new funds will enable Cellestia...
...with data expected at the end of 2020 or in early 2021. He added that Cellestia’s...
BioCentury | Oct 18, 2018
Distillery Therapeutics

Cancer

...could include identifying and testing small molecule Notch 1 inhibitors in models of metastatic medulloblastoma. Cellestia Biotech AG...
BioCentury | Sep 8, 2017
Clinical News

Cellestia to start Phase I/IIa of CB-103 for Notch-dependent cancers

...inhibitor. Cellestia said there are no approved agents targeting NOTCH for the population. In 2014, Cellestia...
...license to IP covering small molecule inhibitors of NOTCH-dependent gene expression, including lead candidate CB-103. Cellestia Biotech AG...
...I) and safety (Phase IIa); preliminary efficacy measures Status: Phase I/IIa start Milestone: N/A Elizabeth S. Eaton CB-103 Cellestia Biotech AG Notch...
BioCentury | Apr 7, 2017
Emerging Company Profile

Up a notch

...By targeting a protein all Notch receptors use to turn on oncogenes, Cellestia Biotech AG ’s molecules could...
...c-Myc) and hairy and enhancer of split (HES). Chairman Freddy Radtke and CSO Rajwinder Lehal, Cellestia’s...
...pathway downstream of the cascade, independent of the reasons for activation,” said Bauer. EPFL granted Cellestia...
BioCentury | Jan 27, 2017
Financial News

Celestia completes venture financing

...Cancer company Cellestia Biotech AG (Basel, Switzerland) raised CHF5.2 million ($5.2 million) in the third and final tranche...
...and private investors participated in the offering, which closed Jan. 26. Cellestia Biotech AG , Basel, Switzerland Alicia Parker Cellestia Biotech AG...
Items per page:
1 - 5 of 5
BioCentury | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

...VC PPF Group, as well as Partners Investment and additional undisclosed investors. Alongside the financing, Cellestia Biotech AG...
...million in non-dilutive funding. CFO Gaudenz von Capeller told BioCentury the new funds will enable Cellestia...
...with data expected at the end of 2020 or in early 2021. He added that Cellestia’s...
BioCentury | Oct 18, 2018
Distillery Therapeutics

Cancer

...could include identifying and testing small molecule Notch 1 inhibitors in models of metastatic medulloblastoma. Cellestia Biotech AG...
BioCentury | Sep 8, 2017
Clinical News

Cellestia to start Phase I/IIa of CB-103 for Notch-dependent cancers

...inhibitor. Cellestia said there are no approved agents targeting NOTCH for the population. In 2014, Cellestia...
...license to IP covering small molecule inhibitors of NOTCH-dependent gene expression, including lead candidate CB-103. Cellestia Biotech AG...
...I) and safety (Phase IIa); preliminary efficacy measures Status: Phase I/IIa start Milestone: N/A Elizabeth S. Eaton CB-103 Cellestia Biotech AG Notch...
BioCentury | Apr 7, 2017
Emerging Company Profile

Up a notch

...By targeting a protein all Notch receptors use to turn on oncogenes, Cellestia Biotech AG ’s molecules could...
...c-Myc) and hairy and enhancer of split (HES). Chairman Freddy Radtke and CSO Rajwinder Lehal, Cellestia’s...
...pathway downstream of the cascade, independent of the reasons for activation,” said Bauer. EPFL granted Cellestia...
BioCentury | Jan 27, 2017
Financial News

Celestia completes venture financing

...Cancer company Cellestia Biotech AG (Basel, Switzerland) raised CHF5.2 million ($5.2 million) in the third and final tranche...
...and private investors participated in the offering, which closed Jan. 26. Cellestia Biotech AG , Basel, Switzerland Alicia Parker Cellestia Biotech AG...
Items per page:
1 - 5 of 5